CYX.V - Calyx Ventures Inc.

TSXV - TSXV Delayed Price. Currency in CAD
0.055
0.000 (0.00%)
At close: 3:12PM EDT
Stock chart is not supported by your current browser
Previous Close0.055
Open0.055
Bid0.055 x 0
Ask0.060 x 0
Day's Range0.055 - 0.055
52 Week Range0.045 - 0.420
Volume132,150
Avg. Volume300,519
Market Cap5.213M
Beta1.90
PE Ratio (TTM)N/A
EPS (TTM)-0.022
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire2 months ago

    Calyx Closes Private Placement

    Calyx Ventures Inc. (CYX.V) (“Calyx” or the “Company”) is pleased to announce that it has completed its non-brokered private placement through the issuance of 9,285,700 units (each, a “Unit”), at a price of $0.07 per Unit, for gross proceeds of $650,000.  Each Unit consists one common share of the Company, and one-half-of-one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant is exercisable to acquire one additional common share of the Company at a price of $0.15 per share for a period of twelve months, subject to accelerated expiry in the event the closing price of the Company’s common shares is $0.20 or higher for ten consecutive trading days.

  • GlobeNewswire2 months ago

    Calyx to Complete Private Placement

    Calyx Ventures Inc. (CYX.V) (“Calyx” or the “Company”) is pleased to announce that it intends to complete a non-brokered private placement of up to 9,285,713 units (each, a “Unit”), at a price of $0.07 per Unit, for gross proceeds of up to $650,000.  Each Unit consists one common share of the Company, and one-half-of-one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant is exercisable to acquire one additional common share of the Company at a price of $0.15 per share for a period of twelve months, subject to accelerated expiry in the event the closing price of the Company's common shares is $0.20 or higher for ten consecutive trading days.

  • ACCESSWIRE5 months ago

    Today’s Research Reports on Concordia International, GeneNews, Medicure and Calyx Ventures

    NEW YORK, NY / ACCESSWIRE / March 5, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE7 months ago

    Today’s Research Reports on Emblem Corp., Cronos Group Inc., Calyx Bio-Ventures Inc. and Theralase Technologies Inc.

    NEW YORK, NY / ACCESSWIRE / January 11, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • ACCESSWIRE10 months ago

    Today's Research Reports on Microbix Biosystems, Essa Pharma, Calyx Bio-Ventures and Revive Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 3, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...